UCLA 23rd Annual Review of Psychiatry and Psychopharmacology Update

UCLA 23rd Annual Review of Psychiatry and Psychopharmacology Update is organized by David Geffen School of Medicine at University of California, Los Angeles (UCLA) and will be held from Nov 02 - 03, 2018 at UCLA Meyer and Renee Luskin Conference Center, Los Angeles, California, United States of America.

The target audience for this medical event is psychiatrists and other physicians, psychologists, social workers, marriage and family therapists, mental health nurses, allied healthcare professionals, psychotherapists, mental health trainees, and researchers. This CME Conference has been approved for a maximum of 15.50 AMA PRA Category 1 Credits.

Course Description :
The Semel Institute for Neuroscience and Human Behavior at UCLA presents the 23rd Annual Review of Psychiatry and Psychopharmacology Update on emerging diagnostic and treatment modalities for mood disorders, as well as other diseases of the mind and brain. This course will run in two tracks. The first track will focus on the latest clinical advances and developments that will shape how clinicians treat patients. The second track will examine how improved understanding of neuroscience and the arts can enhance treatment and contribute to a greater understanding of human behavior. Renowned faculty experts from psychiatry, psychology, neurology, and other fields, will present novel treatments and management strategies to help healthcare professionals deliver state-of-the-art care to their patients. This two-day program will feature lectures as well as symposia with panel discussions that will encourage active participation by the audience and discussion of challenging cases.

Course Objectives :
At the completion of this program, participants should be better able to:
• Utilize the most advanced diagnostic evaluation and treatment strategies for patients with mood, anxiety, or psychotic disorders, as well as other brain diseases
• Identify and implement optimal patient-specific therapies for patients with neuropsychiatric illnesses
• Utilize appropriate neuromodulation therapies for mood disorders
• Compare the relative utility of distinct approaches for managing psychiatric illness
• Recognize the relevance of both neuroscience and the arts to patient care
• Enhance multimodal management of neuropsychiatric illness through the interplay among the arts, neuroscience, and mental disorders

Additional details will be posted as soon as they are available.